Last updated: November 9, 2026
Selpercatinib, sold by Eli Lilly as Retevmo, is a selective RET kinase inhibitor used for RET-altered cancers. Its commercial position has strengthened because it covers multiple RET-driven tumors, has limited direct competition, and benefits from expanded FDA labeling. U.S. revenue has grown from a launch-stage oncology product into a commercially meaningful targeted therapy, with annual global sales estimated at roughly $400 million in 2024 based on Lilly’s reported product results. Patent protection extends into the late 2030s, although regulatory exclusivity expires much earlier and Paragraph IV litigation remains the principal near-term generic-entry risk.
What is selpercatinib approved to treat?
Selpercatinib is approved for cancers driven by activating RET alterations or RET fusions. The FDA indications include:
| Indication |
Relevant biomarker |
FDA status |
| Locally advanced or metastatic RET fusion-positive non-small cell lung cancer |
RET gene fusion |
Regular approval |
| Advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy |
Activating RET mutation |
Regular approval |
| Advanced or metastatic RET fusion-positive thyroid cancer refractory to radioactive iodine |
RET gene fusion |
Regular approval |
| Locally advanced or metastatic solid tumors with a RET gene fusion that progressed after prior systemic treatment or has no satisfactory alternatives |
RET gene fusion |
Accelerated approval pathway |
The initial U.S. approval occurred in May 2020 under the accelerated approval pathway for RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA converted key indications to regular approval in 2022 after confirmatory evidence from the LIBRETTO-001 trial and related clinical data. In 2024, the FDA expanded selpercatinib use to pediatric patients aged 2 years and older with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic treatment and advanced or metastatic RET fusion-positive thyroid cancer requiring systemic treatment that is radioactive-iodine refractory.[1,2]
How large is the selpercatinib market?
The addressable market is concentrated but commercially attractive. RET alterations occur in a small fraction of solid tumors, yet testing is increasingly integrated into comprehensive genomic profiling for advanced non-small cell lung cancer and thyroid cancer.
| Market segment |
Approximate clinical opportunity |
| RET fusion-positive non-small cell lung cancer |
About 1% to 2% of non-small cell lung cancer cases |
| RET-mutant medullary thyroid cancer |
Approximately 60% to 70% of hereditary cases and a meaningful minority of sporadic cases |
| RET fusion-positive thyroid cancer |
More common in selected thyroid cancer subtypes, including younger patients |
| RET fusion-positive solid tumors |
Rare across individual tumor types, but aggregated across cancers |
The commercial market is driven by treatment duration rather than patient volume alone. Patients with advanced RET-driven disease can remain on therapy for extended periods, producing recurring oral-drug revenue. The clinical value proposition is strongest where selpercatinib offers central nervous system activity, durable disease control, and a biomarker-selected treatment option.
Market penetration also depends on diagnostic testing. RET fusions and RET mutations must be identified before treatment, which links selpercatinib demand to next-generation sequencing adoption, reimbursement for molecular diagnostics, and testing rates in community oncology.
What are selpercatinib sales and financial trajectory?
Lilly does not always present Retevmo as a separately detailed major product in the same way as its largest oncology brands. Public company disclosures and earnings materials indicate a strong post-launch growth trajectory.
| Fiscal year |
Approximate Retevmo revenue trend |
Primary growth drivers |
| 2020 |
Launch year |
Initial FDA approval and U.S. launch |
| 2021 |
About $100 million |
Early adoption in RET fusion lung cancer and thyroid cancer |
| 2022 |
About $200 million to $250 million |
Broader physician use and regular-approval conversion |
| 2023 |
About $300 million to $350 million |
Increased testing, longer treatment duration, international expansion |
| 2024 |
Approximately $400 million |
Expanded labeling, pediatric use, continued RET testing and global uptake |
The trajectory has been supported by four commercial factors:
- Selpercatinib is highly selective for RET, limiting some off-target kinase activity associated with broader multikinase inhibitors.
- The drug has activity in central nervous system disease, an important consideration in metastatic lung cancer.
- The competitive field narrowed after the U.S. commercial withdrawal of pralsetinib, sold as Gavreto, by Blueprint Medicines and Rigel Pharmaceuticals.
- The 2024 pediatric expansion increased label breadth and reinforced the drug’s position in RET-mutant thyroid cancer.
Retevmo remains smaller than Lilly’s major oncology products, including Verzenio and Jaypirca. Its commercial profile is more resilient than its patient count suggests because treatment is biomarker-selected, specialist-driven, and often chronic.
When does selpercatinib lose regulatory exclusivity?
Selpercatinib received five-year new chemical entity exclusivity in the United States. Because Retevmo was approved in May 2020, the basic NCE exclusivity period expired in May 2025.
Orphan-drug exclusivity may provide longer protection for specific orphan-designated indications. Orphan exclusivity generally lasts seven years from approval of the applicable indication, subject to the scope of the designation and subsequent regulatory actions. The relevant dates vary by indication rather than applying uniformly to the entire product.
| Protection type |
Approximate timing |
| FDA approval |
May 2020 |
| Five-year NCE exclusivity |
May 2025 |
| Potential seven-year orphan exclusivity for qualifying indications |
2027 or later, depending on indication |
| Patent-based protection |
Late 2030s for key listed patent families |
Regulatory exclusivity does not prevent patent challenges after the NCE period ends. A generic applicant can file an Abbreviated New Drug Application with a Paragraph IV certification before the listed patents expire.
What patents protect selpercatinib?
The central U.S. patent estate covers selpercatinib compounds and pharmaceutical compositions. Key Orange Book-listed patents include patents assigned to Eli Lilly or its relevant corporate predecessors.
| Patent |
General subject matter |
Reported expiration range |
| U.S. Patent No. 10,519,172 |
RET inhibitor compounds, including selpercatinib-related chemical matter |
2037 |
| U.S. Patent No. 10,583,117 |
Pharmaceutical compositions and related compound claims |
Late 2030s |
| U.S. Patent No. 11,168,091 |
Additional composition or formulation protection |
Late 2030s |
| U.S. Patent No. 11,406,636 |
Later-issued patent protection associated with the product estate |
Late 2030s |
The principal composition patent, U.S. Patent No. 10,519,172, has a reported expiration in October 2037 before any applicable patent-term adjustment or pediatric extension. Exact generic-entry timing depends on the patent claims listed in the Orange Book, any terminal disclaimers, patent-term adjustment, litigation outcomes, and settlement terms.[3]
The estate appears stronger than a single-patent product because it includes overlapping compound, composition, formulation, and potentially method-of-use claims. Its commercial strength is highest where the claims cover the active pharmaceutical ingredient itself. Formulation and method-of-use patents generally create additional litigation leverage but may be easier to design around than a valid composition-of-matter patent.
What formulations are protected by selpercatinib patents?
Retevmo is supplied as oral capsules. The commercial product is available in multiple strengths, including 40-mg and 80-mg capsules. Patent protection can cover:
- The active selpercatinib compound.
- Pharmaceutical compositions containing selpercatinib.
- Solid oral dosage forms.
- Dose regimens for RET-driven cancers.
- Use in specific biomarker-defined populations.
- Use following prior systemic treatment or radioactive iodine.
Formulation patents can delay a generic product that uses a materially similar dosage form, but a generic applicant may attempt to avoid infringement through a different excipient system or manufacturing process. Composition-of-matter protection remains the most important barrier because it can cover the active ingredient regardless of formulation.
Are there Paragraph IV challenges to Retevmo?
A Paragraph IV challenge would be the standard U.S. pathway for a generic applicant seeking market entry before patent expiration. Publicly visible litigation and Orange Book activity should be monitored for:
- An ANDA filing with Paragraph IV certifications.
- A 45-day patent-infringement action by Lilly.
- A 30-month stay of FDA approval under the Hatch-Waxman Act.
- A district-court judgment on validity, enforceability, or infringement.
- A settlement granting an authorized or licensed generic launch date.
No high-profile public Paragraph IV litigation has established an early generic launch date for selpercatinib through the publicly available record used for this assessment. The absence of a reported case does not remove future challenge risk. The end of NCE exclusivity in 2025 increases the incentive for generic manufacturers to file.
What is the Orange Book status of selpercatinib?
Retevmo is an FDA-approved small-molecule drug and is eligible for Orange Book listing. The Orange Book identifies patents that Lilly asserts cover the approved drug, including active-ingredient, composition, and related protection. Orange Book status matters because a generic applicant must address each listed patent through Paragraph III or Paragraph IV certification.
The key commercial question is whether a generic applicant can invalidate or avoid the late-2030s composition claims. If the main composition patent survives, the likely U.S. generic launch date will be controlled by patent expiration or a negotiated settlement rather than by the 2025 end of NCE exclusivity.
Which companies compete with selpercatinib?
The main direct competitor is pralsetinib, developed by Blueprint Medicines and commercialized in the United States as Gavreto. Pralsetinib also targets RET-altered cancers and competed directly in RET fusion-positive lung cancer and RET-mutant medullary thyroid cancer.
| Drug |
Company |
Target |
Commercial position |
| Retevmo |
Eli Lilly |
Selective RET inhibitor |
Leading U.S. commercial position |
| Gavreto |
Blueprint Medicines/Rigel |
Selective RET inhibitor |
U.S. commercial withdrawal reduced direct competition |
| Cabozantinib |
Exelixis |
Multikinase inhibitor |
Used in broader thyroid cancer settings |
| Vandetanib |
Sanofi |
Multikinase inhibitor |
Earlier-line or alternative thyroid cancer use |
| Chemotherapy and immunotherapy |
Multiple companies |
Nonselective |
Less biomarker-specific |
Selpercatinib competes less directly with immunotherapies and broad kinase inhibitors than with pralsetinib. In RET-positive disease, treatment selection is influenced by CNS activity, toxicity, prior therapy, physician familiarity, access, and payer restrictions.
How strong is the selpercatinib patent estate?
The patent estate is commercially strong for three reasons:
- The principal active-ingredient patent extends into approximately 2037.
- Multiple listed patents create additional validity and infringement issues for ANDA applicants.
- The drug has several indications, allowing Lilly to combine product patents with method-of-use and orphan exclusivity strategies.
The estate is not risk-free. Potential challenges include obviousness attacks based on prior RET inhibitors, written-description and enablement arguments, claim-construction disputes, and design-around formulations. Method-of-use claims may be vulnerable if a generic label omits the protected indication, although induced-infringement issues can still arise when the use is central to the product’s expected market.
What generic-entry scenarios exist for selpercatinib?
Three launch scenarios are commercially relevant.
Scenario 1: Patent-protected launch near 2037
Lilly preserves the core composition patent, and generic companies defer launch until patent expiration. This is the most favorable scenario for long-term Retevmo revenue.
Scenario 2: Litigation settlement with an earlier licensed launch
A generic applicant files Paragraph IV, Lilly sues, and the parties settle for an agreed entry date before 2037. The settlement could include a licensed generic, a royalty, or restrictions on launch timing and formulation.
Scenario 3: Patent invalidation or non-infringement
A successful challenge could permit generic entry materially before 2037. Revenue would likely decline rapidly because oral targeted oncology products can face substantial price erosion once multiple generics enter.
The risk is concentrated after 2025, when generic applicants can submit ANDAs without waiting for NCE exclusivity to expire.
What biosimilar risk affects selpercatinib?
Selpercatinib is a chemically synthesized small molecule, not a biologic. Biosimilar substitution rules do not apply. The relevant threat is conventional generic competition under the ANDA pathway.
This distinction lowers regulatory complexity for challengers. A generic applicant does not need to reproduce a biologic manufacturing process or establish biosimilarity. The main barriers are patent validity, formulation equivalence, labeling, and commercial scale.
What licensing deals affect selpercatinib?
Selpercatinib originated from research associated with Loxo Oncology. Eli Lilly acquired Loxo in 2019, bringing selpercatinib and other precision-oncology assets into Lilly’s portfolio. The transaction was valued at approximately $8 billion in cash.[4]
The acquisition gave Lilly control of:
- Selpercatinib.
- Loxo-292, the development code for selpercatinib.
- RET-focused intellectual property.
- The Loxo precision-oncology platform.
No major third-party license currently defines the core U.S. commercial rights in the same way that a co-commercialization agreement would. Lilly controls global development and commercialization, subject to regional distribution and collaboration arrangements.
What revenue exposure does Lilly face from selpercatinib?
Retevmo is not a major share of Lilly’s total revenue, which exceeded $30 billion annually by the middle of the decade. Its strategic value is greater than its current revenue contribution because it diversifies Lilly’s oncology portfolio and provides exposure to precision medicine.
Revenue exposure is concentrated in:
- RET testing rates.
- Lung cancer treatment duration.
- Thyroid cancer prevalence and referral patterns.
- International reimbursement.
- Competition from pralsetinib or future RET inhibitors.
- Generic entry after successful Paragraph IV litigation.
A late-2030s patent runway gives Lilly time to expand pediatric use, increase global penetration, and study earlier-line treatment settings. The main financial risk is a faster-than-expected patent challenge rather than immediate competitive displacement.
What patent litigation affects selpercatinib?
The principal litigation risk is future Hatch-Waxman litigation involving the Orange Book-listed patents. A patent case would likely address:
- Validity of the active-ingredient claims.
- Obviousness based on earlier RET inhibitors.
- Written description and enablement.
- Infringement by a generic capsule formulation.
- The scope of method-of-use claims.
- Whether a generic label induces infringement.
There is no established biosimilar litigation pathway because Retevmo is not a biologic. Settlement terms, if litigation begins, would be central to valuation because they could determine the earliest generic entry date.
Key Takeaways
- Selpercatinib is Eli Lilly’s targeted RET inhibitor marketed as Retevmo.
- Its core markets are RET fusion-positive non-small cell lung cancer and RET-altered thyroid cancer.
- Revenue has risen from roughly $100 million in 2021 to an estimated $400 million in 2024.
- U.S. NCE exclusivity ended in May 2025, but orphan exclusivity may extend for specific indications.
- Key Orange Book patents extend into the late 2030s, with U.S. Patent No. 10,519,172 among the central rights.
- Pralsetinib is the principal direct competitor, but its U.S. commercial withdrawal reduced competitive pressure.
- Retevmo faces generic rather than biosimilar risk.
- The largest valuation variable is whether a Paragraph IV challenge produces a settlement, patent invalidation, or entry near the late-2030s expiration date.
FAQs
Is selpercatinib a first-line treatment for RET-positive lung cancer?
Yes. Selpercatinib is an FDA-approved treatment option for locally advanced or metastatic RET fusion-positive non-small cell lung cancer, including use in treatment-naive patients.
Does selpercatinib have central nervous system activity?
Yes. Clinical studies have shown intracranial activity, which supports use in RET fusion-positive lung cancer patients with brain metastases or other central nervous system disease.
Can a generic manufacturer launch selpercatinib in 2025?
Not automatically. The end of five-year NCE exclusivity permits an ANDA filing, but listed patents may block FDA approval or commercial launch until litigation resolves or a settlement permits earlier entry.
Is Retevmo protected by orphan-drug exclusivity?
Specific Retevmo indications received orphan-drug designations. Orphan exclusivity is indication-specific and generally lasts seven years from the applicable approval date.
What is the principal commercial threat to Retevmo?
The principal long-term threat is a successful Paragraph IV patent challenge that permits generic selpercatinib to enter before the late-2030s patent expiration. Near-term competitive risk is lower because pralsetinib has a reduced U.S. commercial presence.
References
-
U.S. Food and Drug Administration. (2024). FDA approves selpercatinib for pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with RET alterations. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2022). FDA grants regular approval to selpercatinib for metastatic RET fusion-positive non-small cell lung cancer. https://www.fda.gov/
-
U.S. Patent and Trademark Office. (2019). U.S. Patent No. 10,519,172, substituted pyridine compounds as RET inhibitors. https://patents.google.com/
-
Eli Lilly and Company. (2019). Lilly to acquire Loxo Oncology, bringing first-in-class medicines and pipeline to Lilly. https://investor.lilly.com/
